1.
Best Pract Res Clin Rheumatol
; 36(2): 101762, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35778272
RESUMO
Idiopathic inflammatory myopathies (IIMs) represent a heterogeneous group of systemic autoimmune diseases characterized by immune-mediated muscle injury. As insights into pathogenesis of IIM evolve, novel therapeutic strategies have become available to optimize outcomes. Herein, we summarize novel and emerging strategies in the management of dermatomyositis (DM), immunemediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM).